Key facts
- Ensweet’s last known valuation is $8.3M (Mar 2025).
- It has raised $5.7M; the latest was Later Stage VC ($3.1M) in Mar 2025.
- Notable investors include XAnge, 50 Partners, IRD Invest, AG2R La Mondiale, Angels Santé — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ensweet
- ·The full record, as it builds
Funding rounds
No funding rounds for Ensweet are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ensweet
Developer of a telemedicine-based rehabilitation system designed for remote therapeutic care intended to extend access to structured cardiac recovery programs. The company's platform includes integrated heart-rate monitoring, physical-activity guidance tools, remote supervision interfaces for healthcare teams, and home-based rehabilitation workflows, enabling patients with cardiac conditions to receive accessible, continuous, and location-independent rehabilitation support while maintaining coordinated communication with multidisciplinary caregivers.
- Sector
- Healthcare
- HQ
- Lille, France
- Founded
- 2020
- Employees
- 18
- Website
- ensweet.fr/
- Ownership
- Privately Held (backing)
Ensweet doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ensweet shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ensweet in its N-PORT filings yet. We sweep new filings monthly.